School of Medicine
Urologic Oncology Program
Area of interest
My career focus is the development of novel treatments for patients with genitourinary (GU) malignancies. I previously led the Genitourinary Oncology Research Program at New York Presbyterian Hospital-Weill Cornell Medical College followed by the development of a premiere clinical and translational research program in urothelial cancer at Memorial Sloan-Kettering Cancer Center (MSKCC). In my role as Section Chief of GU Oncology at UNC, I am focused on the development of a premiere translational and clinical research program in multiple GU-related cancers including prostate, bladder, kidney and testicular cancer. The clinical trials program comprises investigator initiated, cooperative group (ALLIANCE), and pharmaceutical sponsored trials. I work closely with the other members of the GU medical oncology service including Dr. Kim Rathmell, Dr. Young Whang, Dr. Paul Godley, Dr. William Kim and colleagues in the Division of Urology and Department of Radiation Oncology as well as many other investigators at LCCC. I personally continue to focus on clinical trials and translational research in urothelial cancer.
The specific aim of the translational research program is to design GU-specific clinical trials that utilize an integrated genomics approach to characterize tumors for genetic alterations. This goal is predicated on the concept that genomic alterations predict sensitivity or resistance to novel targeted agents. The central tenet is that prospective characterization of tumors in the laboratory will accelerate the development of promising novel agents in the clinic. The foundation for this approach has been established. I was the principal investigator on a completed grant funded by an American Association for Cancer Research (AACR) Henry Shepard Grant for Bladder Cancer Research. This research program, entitled the Bladder Cancer Oncogenome Project, identified molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with urothelial cancer.
A second, clinically oriented goal of the GU program will be to design and conduct trials that specifically address the issues related to the treatment of older adults with cancer. For example, bladder cancer, by virtue of its demographics, can represent a model for the study of multimodality therapy in older adults. Patients afflicted with this malignancy are typically in the 7th and 8th decade of life providing the basis for more global assessments of treatment tolerance and outcomes.
Awards and Honors
2000 Institutional Research Fellowship Award in Hematology (NIH sponsored)
2001 Amgen Research Fellowship Award
2002 NCCN Fellows Recognition Program (sponsored by Ortho Biotech)
2001 ASCO Fellows Travel Grant Program (sponsored by ASCO and Aventis Oncology)
2001 ASCO/AACR Methods in Clinical Cancer Research Workshop
2003 ASCO Merit Award
2004 DOD Prostate Cancer Research Program (PCRP) Physician Research Training Award
2005 AACR Accelerating Anticancer Agent Development and Validation Workshop
2006 Hematology/Oncology Faculty Teaching Award
2007 The MSKCC Paul Sherlock Housestaff Teaching Award